MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer



MedicineWorld.Org - Cancer - Treatment of recurrent ovarian cancer
Your gateway to information on Treatment of recurrent ovarian cancer

MedicineWorld.Org: Treatment of recurrent ovarian cancer

Ovarian Cancer Main Page Ovarian Cancer News Main Cancer Page  


Treatment of recurrent ovarian cancer   

             arcgba.gif
       Patients who had good response to previous chemotherapy and had a remission lasting for more than 6 months is usually retreated with the same drug combination. Others may receive different chemotherapy drugs. The following is a list of chemotherapy drugs commonly used for recurrent ovarian cancer
  • Carboplatin
  • Cisplatin
 
  • Paclitaxel
  • Topotecan
  • Liposomal doxorubicin (Doxil)
  • Gemcitabine
  • Navelbine
  • VP-16

      These agents may put the cancer back in remission for a variable period of time.
 


Treatment of recurrent ovarian cancer

 
BREAST CANCER MAIN PAGE
Home| Breast cancer news | Common terms| Breast cancer treatment|Treatment by stage| Surgical treatment|Chemotherapy|Chemo drugs| Doxorubicin| Cyclophosphamide| Methotrexate| Hormonal therapy| Radiation therapy| Monoclonal therapy| High dose chemotherapy|Recurrent breast cancer|Bisphosphonates |Pregnancy and breast cancer |Risk factors |Risk details |My risk |Comprehensive |Breast cancer statistics |African Americans |Ashkenazi |Asians |Hispanic |Men |Native Americans |Older women |Younger women |Pregnant women |BRCA |Ovarian Cancer |Ovarian Cancer News |Ovarian Cancer News |Ovarian Cancer Statistics |Ovarian Cancer Epidimiology |What causes ovarian cancer |Ovarian cancer risk factors |Ovarian cancer screening |Ovarian cancer symptoms |Treatment of ovarian cancer |Treatment of early ovarian cancer |Treatment of advanced ovarian cancer |Treatment of recurrent ovarian cancer |Radiation therapy and ovarian cancer
 


Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.